{"id":451,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"cagrilintide-amylin-analog-phase-2-evidence","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/de\/cagrilintide-amylin-analog-phase-2-evidence\/","title":{"rendered":"Cagrilintide als langwirksames Amylin-Analogon: Lesen der Phasen-2-Beweise"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">Cagrilintide ist ein langwirksames Amylin-Analogon, das f\u00fcr einmal w\u00f6chentliche Studien entwickelt wurde. Es geh\u00f6rt zu einer anderen Signalkategorie als GLP-1-Rezeptoragonisten, auch wenn sp\u00e4tere klinische Programme Cagrilintid zusammen mit Semaglutid untersucht haben.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">Wichtige Erkenntnisse<\/h2><ul class=\"wp-block-list\"><li>Cagrilintide ist ein Amylin-Analogon; Semaglutid ist ein GLP-1-Rezeptoragonist.<\/li><li>Die 2-Evidenz in der Einzelwirkstoffphase sollte von sp\u00e4teren CagriSema-Kombinationsstudien unterschieden werden.<\/li><li>Den \u00fcberpr\u00fcften FDA-Informationen zufolge ist Cagrilintid kein Bestandteil eines von FDA zugelassenen Arzneimittels.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1672\" height=\"941\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png\" alt=\"Forscher \u00fcberpr\u00fcfen drei Peptidrezeptor-Signalwege in einem molekularbiologischen Labor\" class=\"wp-image-442\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png 1672w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-300x169.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-1024x576.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-768x432.png 768w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-1536x864.png 1536w\" sizes=\"auto, (max-width: 1672px) 100vw, 1672px\" \/><figcaption class=\"wp-element-caption\">Originale Laborillustration der Peptidrezeptorforschung; Die Pfade sind konzeptionell und enthalten keine Versuchsdaten.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">Warum Amylin ein eigenst\u00e4ndiger Forschungspfad ist<\/h2><p class=\"wp-block-paragraph\">Amylin wird zusammen mit Insulin ausgesch\u00fcttet und ist an der n\u00e4hrstoffbezogenen Signal\u00fcbertragung beteiligt. Cagrilintide wurde f\u00fcr eine l\u00e4ngere Exposition im Vergleich zu nativem Amylin entwickelt. Seine Rezeptorpharmakologie und sein molekulares Design sind nicht mit GLP-1, GIP oder Glucagonrezeptor-Agonismus austauschbar.<\/p><h2 class=\"wp-block-heading\">Was die Phase-2-Studie dazu beitr\u00e4gt<\/h2><p class=\"wp-block-paragraph\">In der randomisierten Phase-Studie 2 wurden mehrere Cagrilintid-Dosisgruppen mit Placebo und einem aktiven Vergleichspr\u00e4parat bei Erwachsenen mit \u00dcbergewicht oder Adipositas verglichen. Es bewertete die Ver\u00e4nderung des K\u00f6rpergewichts und der Sicherheit w\u00e4hrend des Studienzeitraums. Das Papier unterst\u00fctzte die weitere Entwicklung, machte Cagrilintid jedoch nicht zu einem zugelassenen Arzneimittel.<\/p><p class=\"wp-block-paragraph\">Bei der Zusammenfassung der Studie sind die n\u00fctzlichen Details Population, Randomisierung, Komparator, Dauer, prim\u00e4rer Endpunkt und Muster unerw\u00fcnschter Ereignisse. Das Kopieren eines maximalen Prozentsatzes ohne diese Qualifikationsmerkmale ist keine ausreichende Beweispr\u00fcfung.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Molek\u00fclklasse<\/strong><span>Langwirksames Amylin-Analogon<\/span><\/div><div class=\"pim-evidence-row\"><strong>Beweistyp<\/strong><span>Randomisierte Phase-2-Studie am Menschen<\/span><\/div><div class=\"pim-evidence-row\"><strong>Entwicklungsgrenze<\/strong><span>Untersuchung; nicht gleichwertig mit zugelassenen Semaglutid-Produkten<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">Einzelagent ist nicht dasselbe wie CagriSema<\/h2><p class=\"wp-block-paragraph\">CagriSema bezieht sich auf die gleichzeitige Verabreichung von Cagrilintid und Semaglutid in bestimmten klinischen Programmen. Ergebnisse aus dieser Kombination k\u00f6nnen nicht als reine Cagrilintid-Ergebnisse dargestellt werden, und keiner der Datens\u00e4tze validiert eine unabh\u00e4ngig bereitgestellte Mischung, es sei denn, \u00c4quivalenz und Produktqualit\u00e4t werden nachgewiesen.<\/p>","protected":false},"excerpt":{"rendered":"<p>Ein quellenbasierter Leitfaden zur Amylin-Rezeptor-Pharmakologie von Cagrilintid, zum Design der Phase-2-Studie und zur Grenze zwischen Einzelwirkstoff- und Kombinationsnachweis.<\/p>","protected":false},"author":1,"featured_media":621,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"320","pim_article_type":"Clinical evidence review","pim_evidence_level":"Randomized phase 2 human trial; investigational single-agent context","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Once-weekly cagrilintide in people with overweight and obesity \u2014 phase 2 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34798060\/\",\"note\":\"Primary randomized phase 2 record; PMID 34798060.\"},{\"title\":\"FDA information on cagrilintide and other unapproved GLP-1-related products\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Current regulatory-status boundary.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-451","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence - NHD<\/title>\n<meta name=\"description\" content=\"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/de\/cagrilintide-amylin-analog-phase-2-evidence\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence\" \/>\n<meta property=\"og:description\" content=\"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/de\/cagrilintide-amylin-analog-phase-2-evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\"},\"wordCount\":284,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\",\"name\":\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/de\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cagrilintide als langwirksames Amylin-Analogon: Lesen der Phasen-2-Beweise \u2013 NHD","description":"Ein quellenbasierter Leitfaden zur Amylin-Rezeptor-Pharmakologie von Cagrilintid, zum Design der Phase-2-Studie und zur Grenze zwischen Einzelwirkstoff- und Kombinationsnachweis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/de\/cagrilintide-amylin-analog-phase-2-evidence\/","og_locale":"de_DE","og_type":"article","og_title":"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence","og_description":"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.","og_url":"https:\/\/nhdbio.com\/de\/cagrilintide-amylin-analog-phase-2-evidence\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Verfasst von":"NHD Technical Team","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"},"wordCount":284,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/","url":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/","name":"Cagrilintide als langwirksames Amylin-Analogon: Lesen der Phasen-2-Beweise \u2013 NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Ein quellenbasierter Leitfaden zur Amylin-Rezeptor-Pharmakologie von Cagrilintid, zum Design der Phase-2-Studie und zur Grenze zwischen Einzelwirkstoff- und Kombinationsnachweis.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Peptidrohstoffe und individuelle Peptidsynthese","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"NHD Technisches Team","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"Das technische Team von NHD verwaltet Katalogdokumentationen und Beweiszusammenfassungen f\u00fcr Forschungszwecke. Rezensierte Artikel verweisen auf von Experten begutachtete Artikel, Studienregister und beh\u00f6rdliche Aufzeichnungen, behalten Nullergebnisse und Studieneinschr\u00e4nkungen bei und unterscheiden ver\u00f6ffentlichte Interventionen von Katalogmaterialien. F\u00fcr die Strukturierung kann AI-unterst\u00fctztes Zeichnen verwendet werden; Quellenverkn\u00fcpfungen und Beweisgrenzen bleiben sichtbar. Bei dieser Arbeit handelt es sich nicht um eine unabh\u00e4ngige Begutachtung oder medizinische Beratung.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/de\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/comments?post=451"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/451\/revisions"}],"predecessor-version":[{"id":520,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/451\/revisions\/520"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media\/621"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media?parent=451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/categories?post=451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/tags?post=451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}